Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study

Prinsenberg, Tamara; Illidge, Joël; Zantkuijl, Paul; Bedert, Maarten; Prins, Maria; Valk, Marc van der; Davidovich, Udi

doi:10.1371/journal.pone.0263654

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sexual health services are cost-effective and critical points to addressing sexual behaviors with risk of HCV acquisition [ 32 , 33 ]. Personalized risk reduction strategies should be recommended according to their practices, the number of sexual partners, and the preventive strategies of choice, independent of their gender or sexual orientation.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

et al. 2023

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

et al. 2023

View full text Add to dashboard Cite

“…In some settings, multi-component interventions including home-based HCV RNA testing and GBM-specific harm reduction supply programmes among those potentially at risk of reinfection have been studied. 25,26 In addition, behavioural interventions have been part of test and treat studies 11 or are currently underway. 27 Whether similar programs specifically for GBM in Australia would be warranted is beyond the scope of this work.…”

Section: Discussionmentioning

confidence: 99%

“…While we observed a decline in HCV reinfection incidence, ongoing HCV RNA testing is likely warranted to detect any new infections, promptly treat them, and sustain HCV elimination efforts to date. In some settings, multi‐component interventions including home‐based HCV RNA testing and GBM‐specific harm reduction supply programmes among those potentially at risk of reinfection have been studied 25,26 . In addition, behavioural interventions have been part of test and treat studies 11 or are currently underway 27 .…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020

Harney,

Sacks‐Davis,

van Santen

et al. 2024

Liver International

View full text Add to dashboard Cite

BackgroundThere is some concern that hepatitis C virus (HCV) reinfection might impact HCV micro‐elimination efforts among gay and bisexual men (GBM) with HIV. However, there is a limited understanding of reinfection incidence in the context of unrestricted government‐funded HCV treatment. We aimed to estimate HCV reinfection incidence among GBM with HIV in Australia from 2016 to 2020.MethodsData were from 39 clinics participating in ACCESS, a sentinel surveillance network for blood borne viruses and sexually transmissible infections across Australia. GBM with HIV who had evidence of treatment or spontaneous clearance with at least one positive HCV RNA test, a subsequent negative HCV RNA test, and at least one additional HCV RNA test between 1st January 2016 and 31st December 2020 were eligible for inclusion. A new HCV RNA positive test and/or detectable viral load was defined as a reinfection. Generalised linear modelling was used to examine trends in reinfection.ResultsAmong 12 213 GBM with HIV who had at least one HCV test, 540 were included in the reinfection incidence analysis, of whom 38 (7%) had evidence of reinfection during the observation period. Over 1124 person‐years of follow‐up, the overall rate of reinfection was 3.4/100PY (95% CI 2.5–4.6). HCV reinfection incidence declined on average 30% per calendar year (Incidence Rate Ratio 0.70, 95% CI 0.54–0.91).ConclusionHCV reinfection incidence has declined among GBM with HIV in Australia since government‐funded unrestricted DAAs were made available. Ongoing HCV RNA testing following cure and prompt treatment for anyone newly diagnosed is warranted to sustain this.

show abstract

“…Condomless anal sex with casual male partners, recent HCV reinfection at enrolment and geographic region were also associated with reinfection. Although modelling of micro-elimination strategies supports behavioural risk reduction (and condomless anal sex had the greatest population attributable risk) [18], empirical evidence demonstrating the effectiveness of sexual behavioural interventions for HCV prevention among GBM are lacking [22][23][24][25]. People at risk for reinfection are recommended to have at least annual HCV RNA testing [13].…”

Section: Discussionmentioning

confidence: 99%

Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study

Martinello

Carson

Valk

et al. 2023

Aids

View full text Add to dashboard Cite

Objective: Reinfection poses a challenge to HCV elimination. This analysis assessed incidence of, and factors associated with reinfection among people treated for recent HCV (duration of infection <12 months). Methods: Participants treated for recent HCV (primary infection or reinfection) in an international randomised trial were followed at three-monthly intervals for up to two years to assess for reinfection. Reinfection incidence was calculated using person-time of observation. Factors associated with HCV reinfection were assessed using Cox proportional hazards regression analysis. Results: Of 222 participants treated for recent HCV, 196 (62% primary infection, 38% reinfection) were included in the cohort at risk for reinfection, of whom 87% identified as gay or bisexual men, 71% had HIV, and 20% injected drugs in the month prior to enrolment. During 198 person-years of follow-up, 28 cases of HCV reinfection were identified among 27 participants, for an incidence of 14.2 per 100 person-years (95%CI 9.8, 20.5). Reinfection was associated with prior HCV reinfection (aHR 2.42; 95%CI 1.08, 5.38), injection drug use post-treatment (aHR 2.53; 95%CI 1.14, 5.59), condomless anal intercourse with casual male partners (aHR 3.32; 95%CI 1.14, 9.65) and geographic region (United Kingdom, aHR 0·21; 95% CI 0.06, 0.75). Among gay and bisexual men, reinfection was also associated with sexualised drug use involving injecting post-treatment (aHR 2.97; 95%CI 1.10, 8.02). Conclusion: High reinfection incidence following treatment for recent HCV among people with ongoing sexual and drug use risk behaviour highlights the need for post-treatment surveillance, rapid retreatment of reinfection, and targeted harm reduction strategies. Clinical trial registration: clinicaltrials.gov Identifier NCT02625909 Funding: National Institutes of Health (R01DA040506). Study medication - Gilead Sciences Inc.

show abstract

Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study

Cited by 6 publications

References 21 publications

Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

Hepatitis C antibody prevalence and active hepatitis C infection in HIV-negative gay, bisexual, and other men who have sex with men in Barcelona and Madrid, Spain (March 2018-March 2021)

Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020

Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study

Contact Info

Product

Resources

About